Teduglutide

Drug Profile

Teduglutide

Alternative Names: ALX-0600; Gattex; Revestive

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator Toronto General Hospital; University of Toronto
  • Developer Shire; Takeda Pharmaceuticals International GmbH
  • Class Peptides
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease

Highest Development Phases

  • Marketed Short bowel syndrome
  • Preclinical Mucositis
  • Suspended Crohn's disease

Most Recent Events

  • 01 Jan 2017 Shire initiates a phase III trial for Short bowel syndrome (In adolescents, In children, In infants, In neonates) in USA (SC) (NCT02954458)
  • 02 Nov 2016 Shire plans a phase III trial for Short bowel syndrome (In adolescents, In children, In infants, In neonates) in USA (SC) (NCT02954458)
  • 01 Nov 2016 Shire initiated enrolment in a phase III trial for Short bowel syndrome (In adolescents, In children, In infants, In neonates) (SC) (NCT02949362)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top